1.
Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019;73(5):1001-1014.e8. doi:10.1016/j.molcel.2018.11.028.
1.
Venema WTU, Voskuil MD, Vila AV, et al. Single-Cell RNA Sequencing of Blood and Ileal T Cells From Patients With Crohn’s Disease Reveals Tissue-Specific Characteristics and Drug Targets. Gastroenterology. 2019;156(3):812-815.e22. doi:10.1053/j.gastro.2018.10.046.
1.
Vazquez F, Sellers WR. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?. Cancer Res. 2021;81(23):5806-5809. doi:10.1158/0008-5472.CAN-21-1784.
1.
Eaton JK, Furst L, Ruberto RA, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16(5):497-506. doi:10.1038/s41589-020-0501-5.
1.
Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-175. doi:10.1038/nature20805.
1.
Diogo D, Tian C, Franklin CS, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018;9(1):4285. doi:10.1038/s41467-018-06540-3.
1.
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. doi:10.1038/nature21386.
1.
Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247-250. doi:10.1038/nature24297.
1.
Scolnick EM. The Path to New Therapies for Schizophrenia and Bipolar Illness. FASEB J. 2017;31(4):1254-1259. doi:10.1096/fj.201700028.
1.
Shee K, Yang W, Hinds JW, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215(3):895-910. doi:10.1084/jem.20171818.